FDA Issues New Policy for Remote Ophthalmic Assessment and Monitoring Devices During COVID-19

Today, the U.S. Food and Drug Administration (FDA) issued an immediately in effect guidance to help expand the capability of remote ophthalmic assessment and monitoring devices. These devices include visual acuity charts, visual field devices, general use ophthalmic cameras, and tonometers.   This guidance is intended to help facilitate patient care while reducing patient and health care provider contact and exposure to COVID-19. This policy reflects FDA's commitment to ease burdens on health care providers and facilities as they face the COVID-19 public health emergency.

Read the Guidance Questions? If you have questions about this guidance, contact the Division of Industry and Consumer Education.